Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis

• Published in: BMC urology 2014-09, Vol.14 (1), p.76-76, Article 76
• Main Authors: Temraz, Sally, Mukherji, Deborah, Farhat, Zein Al Abideen, Nasr, Rami, Charafeddine, Maya, Shahait, Mohammed, Wehbe, Mohammad Rachad, Ghaida, Rami Abou, Gheida, Ibrahim Abu, Shamseddine, Ali
• Format: Article
• Language: English
• Subjects: Acute coronary syndromes; Adult; Aged; Aged, 80 and over; Analysis; Bladder cancer; Blood; Cancer therapies; Carcinoma, Transitional Cell - immunology; Carcinoma, Transitional Cell - surgery; Clinical outcomes; Colleges & universities; Cystectomy; Female; Humans; Kaplan-Meier Estimate; Leukocyte Count; Lymphocytes; Lymphocytes - immunology; Male; Measurement; Middle Aged; Monocytes - immunology; Multivariate analysis; Neoplasm Recurrence, Local; Oncology; Operating systems; Preoperative Period; Rankings; Retrospective Studies; ROC Curve; Statistical analysis; Tumorigenesis; Tumors; Urinary Bladder Neoplasms - immunology; Urinary Bladder Neoplasms - surgery; Urology
• ISSN: 1471-2490; 1471-2490
• DOI: 10.1186/1471-2490-14-76

Inflammation is a critical component of tumorigenesis, and many cancers arise from sites of infection, chronic irritation, and inflammation. Inflammatory cytokines triggered by tumors alter hematologic components, including neutrophil, lymphocyte, and monocyte counts. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios have been shown to be valuable prognostic markers in various types of cancers, including bladder cancer. Risk stratification based on clinicopathologic data is insufficient to support treatment-related choices in patients with bladder cancer. Novel prognostic markers are therefore needed. An elevated pretreatment lymphocyte-to-monocyte ratio (LMR) is reportedly associated with improved overall survival (OS) and a longer time to treatment recurrence (TTR) in some types of cancers. However, these data are lacking in patients with bladder cancer. The aim of the present study was to investigate the effect of the preoperative LMR on OS and TTR in a cohort of patients with bladder cancer. Sixty-eight patients with transitional cell carcinoma of the bladder were included in this retrospective analysis. The associations between a high and low LMR with OS and TTR were analyzed using Kaplan-Meier curves and compared by the log-rank test. In our study cohort, an elevated preoperative LMR was significantly associated with an increased TTR (P = 0.001) and OS (P = 0.020). Patients with an LMR of ≤2.87 showed a median TTR of 2.0 years (95% CI, 0.27-3.73), whereas patients with an LMR of >2.87 had a median TTR of 11.1 years (95% CI, 2.31-19.88) (P = 0.001). Patients with an LMR of ≤2.81 showed a median OS of 2.7 years (95% CI, 0.63-4.70), whereas patients with an LMR of >2.81 had a median OS of 6.0 years (95% CI, 3.60-8.40) (P = 0.020). The clinical stage at diagnosis was the only clinicopathologic feature associated with the LMR, while tumor invasion depth showed borderline significance. The LMR is an easily measured and inexpensive prognostic marker that was significantly correlated with OS and TTR in the present retrospective analysis. However, because of the small sample size in this study, larger multicenter, prospective studies are needed.